ANAPTYSBIO - HOME ABOUT TECHNOLOGY PIPELINE INVESTORS / NEWS CAREERS THERAPEUTIC ANTIBODIES for Severe Disease 123 November 15, 2021 ANAPTYSBIO ANNOUNCES POSITIVE ROSNILIMAB HEALTHY VOLUNTEER PHASE 1 TOP-LINE DATA AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data November 4, 2021 ANAPTYSBIO ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES PIPELINE UPDATES AnaptysBio Announces Third Quarter 2021 Financial Results and Provides Pipeline Updates ABOUT TECHNOLOGY PIPELINE INVESTORS CAREERS ABOUT Overview Strategy Management Board of Directors Research and Development Committee Contact TECHNOLOGY Therapeutic Antibodies Somatic Hypermutation SHM Platform Key Advantages Publications PIPELINE Overview Imsidolimab Rosnilimab ANB032 Partnerships INVESTORS / NEWS Overview News Events Goverance Stock Information Analyst Coverage SEC Filings FAQs Contact CAREERS Overview Job Openings Health and Financial Benefits Overview CONNECT LinkedIn Twitter CONTACT Phone: (858)362-6295 info@anaptysbio.com © 2021 ANAPTYSBIO, INC. ALL RIGHTS RESERVED. PRIVACY POLICY | TERMS OF USE